The combination therapy failed to achieve the efficacy threshold required to advance to stage II.

CV301 is Bavarian Nordic’s cancer immunotherapy candidate, while atezolizumab is a checkpoint inhibitor being developed by Roche.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Stage I of the Phase II trial, which was sponsored by Bavarian Nordic, was performed in 27 patients across two cohorts. The first cohort assessed the combination as first-line treatment in urothelial bladder cancer patients who cannot receive cisplatin-containing chemotherapy.

The second cohort involved second-line therapy of participants who received prior cisplatin-based chemotherapy treatments.

Though clinical efficacy was observed in multiple participants, both cohorts did not meet the pre-defined clinical efficacy criteria to expand patient recruitment into stage II.

Bavarian Nordic president and CEO Paul Chaplin said: “While the results of this study are disappointing, they contribute to our overall understanding of our platform and provide important learnings to refine our approach to equip the body’s immune system with more weapons to fight cancer from within.”

The company is studying a combination of CV301 and checkpoint inhibitors in investigator-sponsored Phase II studies for colorectal and pancreatic cancers.

Bavarian Nordic also announced plans to focus on the development of its BN-Brachyury vaccine candidate, along with its new immuno-oncology strategy of intravenous and intratumoral administration.

BN-Brachyury is undergoing a Phase II trial for advanced chordoma. The company noted that the first stage of this trial demonstrated clinical activity, which in turn facilitated expanded enrolment.

Final results from the trial are expected to be available by late next year.

Bavarian Nordic is also planning for a separate trial of an intravenous formulation of BN-Brachyury.